Glasgow Precision Diagnostics and Therapeutics
Lead Research Organisation:
University of Glasgow
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
- University of Glasgow (Lead Research Organisation)
- Eccel Technologies (Collaboration)
- Aptamer Group (Collaboration)
- Blanson (Collaboration)
- Medicines for Malaria Venture (MMV) (Collaboration)
- Jichi Medical University (Collaboration)
- Zeus Scientific (Collaboration)
- Meko (Collaboration)
- Merlin Circuit Tech Ltd (Collaboration)
- Mologic (Collaboration)
- Aerogen (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- PARI GmbH (Collaboration)
- NHS Scotland (Collaboration)
- EnteroBiotix (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- Chiesi (Collaboration)
- Altex Technologies Corporation (Collaboration)
- Vascular Flow Technologies (Collaboration)
- Zeus Inc (Collaboration)
People |
ORCID iD |
Publications
Bacigalupe R
(2019)
A multihost bacterial pathogen overcomes continuous population bottlenecks to adapt to new host species.
in Science advances
Carini C
(2018)
Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis.
in Journal of translational medicine
Chiang YN
(2019)
Genetic transduction by phages and chromosomal islands: The new and noncanonical.
in PLoS pathogens
Ciges-Tomas JR
(2019)
The structure of a polygamous repressor reveals how phage-inducible chromosomal islands spread in nature.
in Nature communications
Hoare D
(2019)
The Future of Cardiovascular Stents: Bioresorbable and Integrated Biosensor Technology.
in Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Ianniciello A
(2022)
Targeting ULK1 in cancer stem cells: insight from chronic myeloid leukemia
in Autophagy
Ibarra-Chávez R
(2020)
Rebooting Synthetic Phage-Inducible Chromosomal Islands: One Method to Forge Them All.
in Biodesign research
Ibarra-Chávez R
(2023)
Phage-Inducible Chromosomal Islands as a Diagnostic Platform to Capture and Detect Bacterial Pathogens
in Advanced Science
Jenkins L
(2021)
Discovery and Characterization of Novel Antagonists of the Proinflammatory Orphan Receptor GPR84.
in ACS pharmacology & translational science
| Description | Acrodysostosis Patient Support and Research group |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Contribution to new or Improved professional practice |
| Description | Engagement with FAO - Participating in a panel as expert on a Risk profile |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Impact | In Singapore during 2015, Group B Streptococcus (GBS) sequence type 283 (ST283) caused the only reported foodborne outbreak of invasive GBS disease. Over 20 percent of cases were healthy adults without comorbidities, which is unusual for GBS. The outbreak was linked to the consumption of raw freshwater fish. Subsequent investigations found that ST283 GBS has been common among GBS causing disease in humans and in tilapia across Southeast Asia for at least 20 years, whereas it was almost non-existent outside this region. Given the novelty of the outbreak, this risk profile consolidates the current knowledge to identify data gaps about GBS ST283 along the freshwater fish supply chain in Southeast Asia. - 2021. Risk profile - Group B Streptococcus (GBS) - Streptococcus agalactiae sequence type (ST) 283 in freshwater fish. Bangkok. |
| URL | https://www.fao.org/documents/card/en/c/cb5067en |
| Description | DTP 2018-19 University of Glasgow |
| Amount | £6,275,971 (GBP) |
| Funding ID | EP/R513222/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2023 |
| Description | Deciphering Gram-negative phage-inducible chromosomal island strategies for spreading in nature |
| Amount | £710,774 (GBP) |
| Funding ID | MR/S00940X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2019 |
| End | 05/2022 |
| Description | Developing Systems able to identify resistance to certain antibiotics and potential new prophylactic measures |
| Amount | £3,000 (GBP) |
| Funding ID | 12490/13212 |
| Organisation | Daiwa Anglo-Japanese Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 05/2019 |
| Description | Early Stage Covid Pre Seed Grant |
| Amount | £23,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2020 |
| Description | Glasgow - Confidence in Concept 2019 |
| Amount | £582,660 (GBP) |
| Funding ID | MC_PC_19039 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 03/2023 |
| Description | Glasgow 2nd intake 2018 4-Year PhD Studentship (4th) Scheme: Mr Jack Beazer; Ms Emily Gallen; Mr Jithin Kuriakose; Ms Rebecca Rooney (4 years) |
| Amount | £612,156 (GBP) |
| Funding ID | FS/18/58/34179 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2022 |
| Description | Glasgow Knowledge Exchange (GKE) develop wireless antenna vascular graft |
| Amount | £2,000 (GBP) |
| Organisation | University of Glasgow |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Glasgow Knowledge Exchange Fund |
| Amount | £2,000 (GBP) |
| Organisation | University of Glasgow |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Helper and satellite pathogenicity islands: the discovery of two novel subcellular elements with a huge impact on bacterial pathogenesis and evolution |
| Amount | £411,276 (GBP) |
| Funding ID | BB/S003835/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 04/2022 |
| Description | How do REDOX regulators control Apicoplast functions in the parasites causing Toxoplasmosis and Malaria |
| Amount | £333,615 (GBP) |
| Funding ID | MR/S024573/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 09/2022 |
| Description | ICURe |
| Amount | £48,000 (GBP) |
| Organisation | SETsquared Partnership |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 07/2018 |
| Description | John Mercer - VascuStent: Development of therapeutic telemetry |
| Amount | £80,000 (GBP) |
| Organisation | Philips Healthcare |
| Sector | Private |
| Country | Netherlands |
| Start | 08/2022 |
| Description | MRC |
| Amount | £0 (GBP) |
| Funding ID | MR/V035401/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Molecular and patho-physiological analysis of the G protein-coupled receptor GPR84 |
| Amount | £901,395 (GBP) |
| Funding ID | BB/T000562/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 12/2023 |
| Description | New Generation of Nebulisers for Efficient Respiratory Drug Delivery |
| Amount | £159,579 (GBP) |
| Funding ID | 80831 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 06/2021 |
| Description | New Generation of Nebulisers for Precision Respiratory Drug Delivery |
| Amount | £812,899 (GBP) |
| Funding ID | 10016661 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2022 |
| End | 04/2024 |
| Description | Paper-based platform for onsite, rapid and multiplexed pathogen detection in shrimp farms |
| Amount | £252,639 (GBP) |
| Funding ID | BB/T012528/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2020 |
| End | 09/2021 |
| Description | RSE Unlocking Ambition Fellowship |
| Amount | £45,000 (GBP) |
| Organisation | Royal Society of Edinburgh (RSE) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 06/2019 |
| Description | Rapid Onsite Tools to Combat Antimicrobial Resistant Mastitis in Dairy Cattle |
| Amount | £141,747 (GBP) |
| Funding ID | 623818418 |
| Organisation | British Council |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2021 |
| End | 02/2023 |
| Description | SMART Feasibility award from Scottish Enterprise EN |
| Amount | £85,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2021 |
| Description | UofG Reinvigorating Research Award |
| Amount | £40,000 (GBP) |
| Organisation | University of Glasgow |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 12/2021 |
| Title | Autophagy/ULK1 deficient cell line models |
| Description | We have generated autophagy/ULK1 deficient cell line models that are shared with the leukaemia/autophagy research community upon request. |
| Type Of Material | Cell line |
| Year Produced | 2019 |
| Provided To Others? | Yes |
| Impact | Used further within leukaemia/autophagy research community. |
| Title | Novel knock-in transgenic mouse line expressing human GPR84 |
| Description | Generated both a novel knock-in transgenic mouse line expressing human GPR84, in collaboration with the company 7TM antibodies. |
| Type Of Material | Cell line |
| Year Produced | 2021 |
| Provided To Others? | Yes |
| Impact | Collaboration with company 7TM antibodies enabling further analysis. |
| URL | https://uk.7tmantibodies.com/ |
| Title | Phospho-site specific antisera against GPR84 |
| Description | Generated a number of phospho-site specific antisera against GPR84 that are now available commercially. |
| Type Of Material | Antibody |
| Year Produced | 2021 |
| Provided To Others? | Yes |
| Impact | Now commercially available through collaboration with company, 7TM antibodies. |
| URL | https://uk.7tmantibodies.com/7tm-phosphosite-specific-antibodies/free-fatty-acid-receptors/ |
| Title | AI algorithm for diagnosis cell populations - Vascular Graft |
| Description | Development of Artificial Intelligence (AI) algorithm for discerning different cell populations for diagnosis or cell killing. |
| Type Of Material | Data analysis technique |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | N/A |
| Description | Aptamer Group in-kind contribution |
| Organisation | Aptamer Group |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Image based screening of aptamer libraries for novel immunomodulators. Dr. James Brewer's team expanded analysis of enriched aptamer pool. |
| Collaborator Contribution | Costs of aptamer synthesis and labelling have been subsidised by Aptamer Group as an in-kind contribution to the project. |
| Impact | Aptamer analysis pool expanded, toll receptor test completed, formulation optimised. |
| Start Year | 2019 |
| Description | Bacteriocins for microbiome engineering |
| Organisation | Enterobiotix |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Identification, production and characterisation of bacteriocins targeting vancomycin-resistant Enterococci. |
| Collaborator Contribution | The project was 50% funded by our industrial partner EnteroBiotix, who provided £33,229 in cash. |
| Impact | N/A |
| Start Year | 2018 |
| Description | EnteroBiotix Collaboration - Dr. D. Walker protein antibiotics active against Vancomycin Resistant Enterococcus |
| Organisation | Enterobiotix |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Walkers team identifying, characterising and engineering of highly specific protein antibiotics active against Vancomycin Resistant Enterococcus (VRE) |
| Collaborator Contribution | This project was 50% funded by our industrial partner EnteroBiotix, who provided £33,229 in cash. We have held monthly meetings with EnteroBiotix throughout the project. |
| Impact | Candidates were identified and produced, in vitro activity and stability was successfully tested, leading to accelerated and long term stability testing of the compounds. |
| Start Year | 2019 |
| Description | Enterobiotix |
| Organisation | Enterobiotix |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Testing the concept for development of new class of medicine |
| Collaborator Contribution | development of the medicine |
| Impact | Ongoing |
| Start Year | 2018 |
| Description | Jichi Medical University |
| Organisation | Jichi Medical University |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | Dr. Kiga Kotaro (Jichi Medical University) spent 2 moths at the University of Glasgow to collaborate on project entitled 'Development of a novel biotechnology-derived antimicrobial approach for therapy and diagnostics using synthetic Phage-Inducible Chromosomal Islands (PICIs).' |
| Collaborator Contribution | Dr. Rodrigo Ibarra-Chavez (University of Glasgow) spent 1 month in Japan at Jichi Medical University. |
| Impact | Two papers: 10.34133/2020/5783064 and 10.1038/s41467-020-16731-6. Awarded Daiwa Support Award for travel to Japan from the Daiwa Anglo-Japanese Foundation. |
| Start Year | 2019 |
| Description | Medicines for Malaria Venture |
| Organisation | Medicines for Malaria Venture (MMV) |
| Country | Switzerland |
| Sector | Charity/Non Profit |
| PI Contribution | Partnership to help seek and generate networking opportunities to gain investment and industry collaborations. |
| Collaborator Contribution | Generation of networking opportunities |
| Impact | Industry negotiations now underway with potential manufacturer. |
| Start Year | 2019 |
| Description | Nebu-Flow Ltd industrial partnerships |
| Organisation | Aerogen |
| Country | Ireland |
| Sector | Private |
| PI Contribution | A spin-out company from University of Glasgow, Nebu-Flow, was formed in March 2019 and has successfully engaged with leading companies in the field who evaluated the technology. This enabled the team to identify the shortcoming of current devices around limited acceptable formulations, including biologics, suspensions and surface-active molecules. They have shown that they can increase inhalable fraction to above 90% (up to 60% higher than current devices in the market). |
| Collaborator Contribution | The industrial partnership was pursued during this project through industry engagements and validation of the technology with leading medical device companies including Pari GmbH and Aerogen Ltd. Both companies evaluated the technology and currently engaged in co-development agreement discussions. |
| Impact | Technology evaluation and currently engagement in the co-development of a miniaturised platform. |
| Start Year | 2020 |
| Description | Nebu-Flow Ltd industrial partnerships |
| Organisation | PARI GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | A spin-out company from University of Glasgow, Nebu-Flow, was formed in March 2019 and has successfully engaged with leading companies in the field who evaluated the technology. This enabled the team to identify the shortcoming of current devices around limited acceptable formulations, including biologics, suspensions and surface-active molecules. They have shown that they can increase inhalable fraction to above 90% (up to 60% higher than current devices in the market). |
| Collaborator Contribution | The industrial partnership was pursued during this project through industry engagements and validation of the technology with leading medical device companies including Pari GmbH and Aerogen Ltd. Both companies evaluated the technology and currently engaged in co-development agreement discussions. |
| Impact | Technology evaluation and currently engagement in the co-development of a miniaturised platform. |
| Start Year | 2020 |
| Description | Novel Platform for Precision Pulmonary Delivery of High Value Therapeutics |
| Organisation | Aerogen |
| Country | Ireland |
| Sector | Private |
| PI Contribution | Development of novel nebuliser technology |
| Collaborator Contribution | Testing of proprietary formulation using nebuliser technology |
| Impact | In development |
| Start Year | 2019 |
| Description | Novel Platform for Precision Pulmonary Delivery of High Value Therapeutics |
| Organisation | Chiesi |
| Country | Italy |
| Sector | Private |
| PI Contribution | Development of novel nebuliser technology |
| Collaborator Contribution | Testing of proprietary formulation using nebuliser technology |
| Impact | In development |
| Start Year | 2019 |
| Description | Novel Platform for Precision Pulmonary Delivery of High Value Therapeutics |
| Organisation | PARI GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Development of novel nebuliser technology |
| Collaborator Contribution | Testing of proprietary formulation using nebuliser technology |
| Impact | In development |
| Start Year | 2019 |
| Description | Partnership with Mologic Ltd |
| Organisation | Mologic |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Dr. J. Reboud & Prof. J. Cooper have established a partnership with Mologic Ltd on the same grants, with a broad remit from human diagnostics to aquaculture for their project entitled 'Translation of origami LAMP research into a novel point-of-care diagnostic for Group B Streptococcus (GBS).' The team collaborate on several applications with Mologic ltd. |
| Collaborator Contribution | Mologic ltd.based initially around work in aquaculture but now including aspects of human health are developing rapid diagnostic tests for a range of diseases, including with the UK Government on COVID-19. This has enabled Reboud to go through design iterations of a swab-based sample preparation system, taking into account the company's knowledge of end-users perceptions, as well as potential for manufacturability. |
| Impact | 3 rounds of further funding; BB/T012528/1, AH/V000586/1 and MR/V035401/1. |
| Start Year | 2020 |
| Description | Smart Stent - Meko Inc |
| Organisation | Meko |
| Country | Germany |
| Sector | Private |
| PI Contribution | Development of a SMART intravascular biosensor for Cardiovascular disease; design, fabricate and test a working prototype device by transitioning our 2D sensor onto a flexible substrate. |
| Collaborator Contribution | Aiding in the manufacturing of medical devices. Dr. J. Mercer partnered with Meko Inc and moved from a purely 3D printed design to a mass producible custom stent and custom graft that incorporates a new sensor platform. |
| Impact | The sensor and graft approach was identified as optimal as advances in the telemetry package can be included extravascularly, this make surgical deployment realistic and helped us identify AVGrafts as the best device class. Work still ongoing. |
| Start Year | 2020 |
| Description | Smart Stent Commercial Collaborators |
| Organisation | Altex Technologies Corporation |
| Country | United States |
| Sector | Private |
| PI Contribution | Mercers group fabricated flexible sensors for the stent device, incorporated the sensor onto the device prototype and developed a telemetry system and software with a iOS/android interface to link the device to a handheld device. |
| Collaborator Contribution | All partners aid in the future refinement of the project. In 2020 both Alter, Meko and Zeus were able to produce scalable product for Mercer and continue to develop required post processing steps. After successful trials, Meko Inc. mass produced the custom stents. |
| Impact | Scalable device now made. Gained the support of 2 additional clinicians with an interest in this area to ensure the compliance and direction of the work. Clinical advisor group formalised. Designed bespoke AI algorithms to aid the measurement analysis from the sensor. |
| Start Year | 2019 |
| Description | Smart Stent Commercial Collaborators |
| Organisation | Blanson |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Mercers group fabricated flexible sensors for the stent device, incorporated the sensor onto the device prototype and developed a telemetry system and software with a iOS/android interface to link the device to a handheld device. |
| Collaborator Contribution | All partners aid in the future refinement of the project. In 2020 both Alter, Meko and Zeus were able to produce scalable product for Mercer and continue to develop required post processing steps. After successful trials, Meko Inc. mass produced the custom stents. |
| Impact | Scalable device now made. Gained the support of 2 additional clinicians with an interest in this area to ensure the compliance and direction of the work. Clinical advisor group formalised. Designed bespoke AI algorithms to aid the measurement analysis from the sensor. |
| Start Year | 2019 |
| Description | Smart Stent Commercial Collaborators |
| Organisation | Eccel Technologies |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Mercers group fabricated flexible sensors for the stent device, incorporated the sensor onto the device prototype and developed a telemetry system and software with a iOS/android interface to link the device to a handheld device. |
| Collaborator Contribution | All partners aid in the future refinement of the project. In 2020 both Alter, Meko and Zeus were able to produce scalable product for Mercer and continue to develop required post processing steps. After successful trials, Meko Inc. mass produced the custom stents. |
| Impact | Scalable device now made. Gained the support of 2 additional clinicians with an interest in this area to ensure the compliance and direction of the work. Clinical advisor group formalised. Designed bespoke AI algorithms to aid the measurement analysis from the sensor. |
| Start Year | 2019 |
| Description | Smart Stent Commercial Collaborators |
| Organisation | Meko |
| Country | Germany |
| Sector | Private |
| PI Contribution | Mercers group fabricated flexible sensors for the stent device, incorporated the sensor onto the device prototype and developed a telemetry system and software with a iOS/android interface to link the device to a handheld device. |
| Collaborator Contribution | All partners aid in the future refinement of the project. In 2020 both Alter, Meko and Zeus were able to produce scalable product for Mercer and continue to develop required post processing steps. After successful trials, Meko Inc. mass produced the custom stents. |
| Impact | Scalable device now made. Gained the support of 2 additional clinicians with an interest in this area to ensure the compliance and direction of the work. Clinical advisor group formalised. Designed bespoke AI algorithms to aid the measurement analysis from the sensor. |
| Start Year | 2019 |
| Description | Smart Stent Commercial Collaborators |
| Organisation | Zeus Scientific |
| Country | United States |
| Sector | Private |
| PI Contribution | Mercers group fabricated flexible sensors for the stent device, incorporated the sensor onto the device prototype and developed a telemetry system and software with a iOS/android interface to link the device to a handheld device. |
| Collaborator Contribution | All partners aid in the future refinement of the project. In 2020 both Alter, Meko and Zeus were able to produce scalable product for Mercer and continue to develop required post processing steps. After successful trials, Meko Inc. mass produced the custom stents. |
| Impact | Scalable device now made. Gained the support of 2 additional clinicians with an interest in this area to ensure the compliance and direction of the work. Clinical advisor group formalised. Designed bespoke AI algorithms to aid the measurement analysis from the sensor. |
| Start Year | 2019 |
| Description | University of Glasgow - University of Edinburgh Smart Stent |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The University of Glasgow supported this project with £10K of funds to support Dr. J. Mercer's (UofG) project to develop a SMART intravascular biosensor for Cardiovascular disease to aid in the design, fabrication and testing of a working prototype device. |
| Collaborator Contribution | The University of Edinburgh also provided ~£65K to part fund the 2xPDRA who worked on this project. |
| Impact | Further funding from the Glasgow Knowledge Exchange fund was awarded. Industry collaborations were established to manufacture the devices at a larger scale. |
| Start Year | 2020 |
| Description | University of Glasgow - University of Edinburgh Smart Stent |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The University of Glasgow supported this project with £10K of funds to support Dr. J. Mercer's (UofG) project to develop a SMART intravascular biosensor for Cardiovascular disease to aid in the design, fabrication and testing of a working prototype device. |
| Collaborator Contribution | The University of Edinburgh also provided ~£65K to part fund the 2xPDRA who worked on this project. |
| Impact | Further funding from the Glasgow Knowledge Exchange fund was awarded. Industry collaborations were established to manufacture the devices at a larger scale. |
| Start Year | 2020 |
| Description | VascuSens Graft Development - JM Stent Custom Graft Fabrication |
| Organisation | Eccel Technologies |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | UofG Reinvigorating Research Award, Wellcome and MRC funding utilised to develop graft technology; three researchers in UofG supported and working on graft and sensor development. |
| Collaborator Contribution | 1) Zeus Inc - contract service for custom graft fabrication and regular supply of samples and service to the value or £2000. 2) Vascular flow Ltd - contract services and collaborator on sensor encapsulation and Arran Biomedical Ltd for secondary processing. 3) Merlin Ltd - contract service from sensor array design and fabrication 4) NHS - lead clinical advisor and lead surgeon on porcine trial 5) Eccel Technologies Ltd - contract service for custom PCB and encapsulation design service in kind to the value of £2000. |
| Impact | Follow on funding awarded. Multidisciplinary: UofG School of Engineering, College of Medical, Veterinary and Life Sciences Bioelectronics Unit. |
| Start Year | 2020 |
| Description | VascuSens Graft Development - JM Stent Custom Graft Fabrication |
| Organisation | Merlin Circuit Tech Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | UofG Reinvigorating Research Award, Wellcome and MRC funding utilised to develop graft technology; three researchers in UofG supported and working on graft and sensor development. |
| Collaborator Contribution | 1) Zeus Inc - contract service for custom graft fabrication and regular supply of samples and service to the value or £2000. 2) Vascular flow Ltd - contract services and collaborator on sensor encapsulation and Arran Biomedical Ltd for secondary processing. 3) Merlin Ltd - contract service from sensor array design and fabrication 4) NHS - lead clinical advisor and lead surgeon on porcine trial 5) Eccel Technologies Ltd - contract service for custom PCB and encapsulation design service in kind to the value of £2000. |
| Impact | Follow on funding awarded. Multidisciplinary: UofG School of Engineering, College of Medical, Veterinary and Life Sciences Bioelectronics Unit. |
| Start Year | 2020 |
| Description | VascuSens Graft Development - JM Stent Custom Graft Fabrication |
| Organisation | NHS Scotland |
| Department | NHS 24 |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | UofG Reinvigorating Research Award, Wellcome and MRC funding utilised to develop graft technology; three researchers in UofG supported and working on graft and sensor development. |
| Collaborator Contribution | 1) Zeus Inc - contract service for custom graft fabrication and regular supply of samples and service to the value or £2000. 2) Vascular flow Ltd - contract services and collaborator on sensor encapsulation and Arran Biomedical Ltd for secondary processing. 3) Merlin Ltd - contract service from sensor array design and fabrication 4) NHS - lead clinical advisor and lead surgeon on porcine trial 5) Eccel Technologies Ltd - contract service for custom PCB and encapsulation design service in kind to the value of £2000. |
| Impact | Follow on funding awarded. Multidisciplinary: UofG School of Engineering, College of Medical, Veterinary and Life Sciences Bioelectronics Unit. |
| Start Year | 2020 |
| Description | VascuSens Graft Development - JM Stent Custom Graft Fabrication |
| Organisation | Vascular Flow Technologies |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | UofG Reinvigorating Research Award, Wellcome and MRC funding utilised to develop graft technology; three researchers in UofG supported and working on graft and sensor development. |
| Collaborator Contribution | 1) Zeus Inc - contract service for custom graft fabrication and regular supply of samples and service to the value or £2000. 2) Vascular flow Ltd - contract services and collaborator on sensor encapsulation and Arran Biomedical Ltd for secondary processing. 3) Merlin Ltd - contract service from sensor array design and fabrication 4) NHS - lead clinical advisor and lead surgeon on porcine trial 5) Eccel Technologies Ltd - contract service for custom PCB and encapsulation design service in kind to the value of £2000. |
| Impact | Follow on funding awarded. Multidisciplinary: UofG School of Engineering, College of Medical, Veterinary and Life Sciences Bioelectronics Unit. |
| Start Year | 2020 |
| Description | VascuSens Graft Development - JM Stent Custom Graft Fabrication |
| Organisation | Zeus Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | UofG Reinvigorating Research Award, Wellcome and MRC funding utilised to develop graft technology; three researchers in UofG supported and working on graft and sensor development. |
| Collaborator Contribution | 1) Zeus Inc - contract service for custom graft fabrication and regular supply of samples and service to the value or £2000. 2) Vascular flow Ltd - contract services and collaborator on sensor encapsulation and Arran Biomedical Ltd for secondary processing. 3) Merlin Ltd - contract service from sensor array design and fabrication 4) NHS - lead clinical advisor and lead surgeon on porcine trial 5) Eccel Technologies Ltd - contract service for custom PCB and encapsulation design service in kind to the value of £2000. |
| Impact | Follow on funding awarded. Multidisciplinary: UofG School of Engineering, College of Medical, Veterinary and Life Sciences Bioelectronics Unit. |
| Start Year | 2020 |
| Title | DEVICE AND METHOD FOR THE NEBULISATION OF LIQUIDS |
| Description | A device is disclosed for the preparation of nebulised droplets, for inhalation. The device has: a surface acoustic wave (SAW) transmission surface; a SAW transducer adapted to generate and propagate SAWs along the SAW transmission surface; and an array of cavities opening at the SAW transmission surface for containing a liquid. In operation, SAWs propagating along the SAW transmission surface interact with the liquid in the cavities to produce nebulised droplets of the liquid. Operation of the device results in a nebulised plume of droplets of average diameter in the range 1-5µm. |
| IP Reference | CA2967124 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Yes |
| Impact | Spin-out company, Acu-Flow Ltd (SC624449). |
| Title | NEBULISATION OF LIQUIDS |
| Description | A device is disclosed for the preparation of nebulised droplets, for inhalation. The device has: a surface acoustic wave (SAW) transmission surface; a SAW transducer adapted to generate and propagate SAWs along the SAW transmission surface; and an array of cavities opening at the SAW transmission surface for containing a liquid. In operation, SAWs propagating along the SAW transmission surface interact with the liquid in the cavities to produce nebulised droplets of the liquid. Operation of the |
| IP Reference | EP3218033 |
| Protection | Patent granted |
| Year Protection Granted | 2017 |
| Licensed | Yes |
| Impact | Spin-out company, Acu-Flow Ltd (SC624449). |
| Title | NEBULISATION OF LIQUIDS |
| Description | A device is disclosed for the preparation of nebulised droplets, for inhalation. The device has: a surface acoustic wave (SAW) transmission surface; a SAW transducer adapted to generate and propagate SAWs along the SAW transmission surface; and an array of cavities opening at the SAW transmission surface for containing a liquid. In operation, SAWs propagating along the SAW transmission surface interact with the liquid in the cavities to produce nebulised droplets of the liquid. Operation of the device results in a nebulised plume of droplets of average diameter in the range 1-5µm. |
| IP Reference | WO2016075209 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Yes |
| Impact | Spin-out company Acu-Flow Ltd (SC624449). |
| Title | Nebulisation of Liquids |
| Description | A device is disclosed for the preparation of nebulised droplets, for inhalation. The device has: a surface acoustic wave (SAW) transmission surface; a SAW transducer adapted to generate and propagate SAWs along the SAW transmission surface; and an array of cavities opening at the SAW transmission surface for containing a liquid. In operation, SAWs propagating along the SAW transmission surface interact with the liquid in the cavities to produce nebulised droplets of the liquid. Operation of the device results in a nebulised plume of droplets of average diameter in the range 1-5 µm. |
| IP Reference | US2017333644 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Yes |
| Impact | Spin-out company Acu,-Flow Ltd (SC624449). |
| Title | Nebulisation of Liquids |
| Description | A device is disclosed for the preparation of nebulised droplets, for inhalation. The device has: a surface acoustic wave (SAW) transmission surface; a SAW transducer adapted to generate and propagate SAWs along the SAW transmission surface; and an array of cavities opening at the SAW transmission surface for containing a liquid. In operation, SAWs propagating along the SAW transmission surface interact with the liquid in the cavities to produce nebulised droplets of the liquid. Operation of the device results in a nebulised plume of droplets of average diameter in the range 1-5µm. |
| IP Reference | GB1420061.2A |
| Protection | Patent application published |
| Year Protection Granted | |
| Licensed | Yes |
| Impact | Spin-out created Acu-Flow Ltd (SC624449). |
| Title | Nebulisation of liquids |
| Description | A device is disclosed for the preparation of nebulised droplets, for inhalation. The device has: a surface acoustic wave (SAW) transmission surface; a SAW transducer adapted to generate and propagate SAWs along the SAW transmission surface; and an array of cavities opening at the SAW transmission surface for containing a liquid. In operation, SAWs propagating along the SAW transmission surface interact with the liquid in the cavities to produce nebulised droplets of the liquid. Operation of the device results in a nebulised plume of droplets of average diameter in the range 1-5µm. |
| IP Reference | AU2015345130 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Yes |
| Impact | Spin-out company, Acu-Flow Ltd (SC624449). |
| Title | App software for vascular data |
| Description | iOS/Android App software for wireless interrogation of data sets. |
| Type Of Technology | Webtool/Application |
| Year Produced | 2022 |
| Impact | N/A |
| Title | HCV-GLUE |
| Description | The Genes Linked by Underlying Evolution (GLUE), software system is to enable a range of sequence data resources for various viruses. GLUE is a toolkit for storage and data analysis with functionalities for diagnostic and viral analysis problems. Projects with viral sequence DNA are hosted within GLUE. |
| Type Of Technology | Webtool/Application |
| Year Produced | 2017 |
| Open Source License? | Yes |
| Impact | collaboration with Public Health England |
| URL | http://tools.glue.cvr.ac.uk/#/home |
| Company Name | Nebu-Flow Ltd (previously Acu-Flow Ltd) |
| Description | A spin-out company, Nebu-Flow Ltd., was formed in March 2019 with the aim to transform respiratory drug delivery platform, commercialising the nebuliser technology. |
| Year Established | 2019 |
| Impact | They have shown that we can increase inhalable fraction to above 90% (up to 60% higher than current devices in the market). |
| Website | https://nebuflow.com/ |
| Company Name | PROTOBIOTIX LIMITED |
| Description | for development of novel therapeutics |
| Year Established | 2018 |
| Impact | none yet |
| Description | Oxford Global inhalation Drug Delivery formulations 2021 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Senior experts in the pharmaceutical science community to address critical strategic developments and technical innovation in formulation, drug delivery and drug product development. Over 500 pharmaceutical scientists working across formulation, drug delivery and drug product manufacturing science & technologies, representing global pharmaceutical organisations, leading biotechnology companies and internationally-renowned academic institutions. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.oxfordglobal.co.uk/formulation-delivery-series-uk-virtual/formulation/ |
| Description | Presentation at Formulation & Delivery Series UK 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Presentation given |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.oxfordglobal.co.uk/formulation-delivery-series-uk/ |
| Description | Presentation at Glasgow Microbiology Collective 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Conference event |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://twitter.com/glasgowmicrocol?lang=en |
| Description | Presentation at MicroTAS 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation given. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://microtas2019.org/ |
| Description | presentation at Phages 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation - 'Synthetic Phage-inducible Chromosomal Islands, the Trojan Horse against AMR' |
| Year(s) Of Engagement Activity | 2019 |
| URL | http://lpmhealthcare.com/phages-2019/speakers-agenda/ |